Update on Effectiveness and Impact of PCV13 use among U.S. Children

Matthew R. Moore, MD, MPH Captain, USPHS Centers for Disease Control & Prevention 23 October 2013



Context:


13-valent pneumococcal conjugate vaccine (PCV13)

- FDA Licensure
 - February 2010
 - Based on non-inferior immunogenicity against serotypes common to both PCV13 and PCV7
 - No randomized controlled trial with clinical endpoints
- ACIP Recommendations
 - February 2010 for all infants at 2, 4, 6, 12-15 months
 - Infants who started schedule with PCV7 recommended to finish routine doses with PCV13
 - "Serotype catch-up" for children fully vaccinated with PCV7: a single "supplemental" dose PCV13 for all children <5 years
- Coverage among 19-35 month-olds during 2012*:
 - − ≥3 doses: 92.3% +/- 0.8%
 - ≥4 doses: 81.9% +/- 1.1%

Methods


- CDC monitors invasive pneumococcal disease (IPD) using active, population-based surveillance conducted in 10 areas around U.S.
- Evaluated cumulative counts of IPD
- Modeled observed vs. expected counts of IPD
- Case-control study of vaccine effectiveness (VE) among children 2-59 months old

Cumulative Cases of PCV5-type IPD among children <<u>5 years old</u>, 2006-2013




"PCV5" types include those in PCV13 but not in PCV7.

Cumulative Cases of PCV5-type IPD among adults >64 years old, 2006-2013




"PCV5" types include those in PCV13 but not in PCV7.

Observed vs. Expected Cases of PCV5-type IPD among Children <5 years old, July 2004-June 2012



Observed vs. Expected cases of PCV5-type IPD among Adults \geq 65 years old, July 2004-June 2012




7

Percent Change in PCV5-type IPD, Comparing Observed Cases to Cases Expected in Absence of PCV13, by age

Age group,	Percent Decrease in Rate (95%IE)		
years	2010-11	2011-12	
<5	67 (62, 70)	88 (86, 89)	
5-17	35 (22, 45)	59 (48, 66)	
18-49	33 (26, 38)	65 (60, 68)	
50-64	24 (18, 28)	54 (51, 58)	
<u>></u> 65	23 (13, 31)	47 (39, 53)	

Statistically significant reductions in vaccine-type IPD in all age groups within first 2 years after PCV13 introduction.

National Cases & Deaths of PCV5-type IPD Prevented following PCV13 Introduction, July 2010-June 12



Case-Control Study of PCV13 Effectiveness: Preliminary Estimates

- Cases: 2-59 month-old children with IPD residing in 10 ABCs areas, New York City, Los Angeles County, Utah
- Controls: 4 per case matched on age (+/- 2wks) & zip code
- May 2010-May 2013
 - Enrolled 765 cases
 - 224 (29%) had PCV13-type IPD
 - 209 (93%) were caused by serotypes 19A, 7F, and 3
 - Enrolled 2274 controls (mean 3 controls per case)
 - Receipt of ≥1 dose among controls increased from 37% in June-November 2010 to 96% in December 2012-May 2013

Outcome	VE <u>></u> 1 dose, %	95% CI
All IPD	65	52-75
PCV13-type IPD	89	79-95
Serotypes 19A, 7F, 3 (as a group)	89	79-95
Serotypes 19A, 7F (as a group)	93	82-97

Summary

- 89% effectiveness of \geq 1 dose PCV13 vs. PCV13-type IPD
- 88% reduction in PCV5-type IPD among children
- 47% reduction in PCV5-type IPD among adults <u>>65</u> years old
- >20,000 cases of IPD and >2,000 deaths prevented

Conclusions

- PCV13 appears highly effective at preventing IPD among children who receive the vaccine.
- Substantial indirect effects are evident after 3 years of use.

California EIP

- Art Reingold
- Duc Vugia
- James Watt
- Gretchen Rothrock
- Pam Daily
- Joelle Nadle
- Mirasol Apostol
- Katie Wymore
- Lauren Pasutti
- Erin Garcia
- Erin Parker
- Mariah Hamilton
- Nick Czap

Los Angeles County DPH

- Laurene Mascola
- Ramon Guevara
- Tasneem Motala
- Colorado EIP
 - Ken Gershman
 - Deborah Aragon
 - Jen Sadlowski
 - Ben White
 - Wendy Bamberg

Connecticut EIP

- Matt Carter
- Terry Rabatsky-Ehr
- Heather Altier
- Susan Petit
- Carmen Marquez
- Michelle Wilson

Georgia EIP

- Monica Farley
- Wendy Baughman
- Janine Ladson
- Amy Holst
- Stepy Thomas
- Sasha Schlicher
- Suzanne Segler
- Lauren Lorenztson
 Matt Crist
- Matt Crist
- Jessica Reno
- Lewis Perry
- Calista Schenck
- Melissa Tobin D'Angelo

Acknowledgments

New York EIP

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

Oregon EIP

Gus Birkhead

Deb Blog

Nancy Bennett

Shelley Zansky

Nancy Spina

Jillian Karr

Kari Burzlaff

Glenda Smith

Suzanne Solghan

Salvatore Currenti

Kimberlee Musser

Ghinwa Dumvati

Greg Giambrone

Nellie Dumas

Anita Gellert

Gary Hollick

Paul Cieslak

Ann Thomas

Rachel Linz

Tim Jones

Brenda Barnes

Mellnda Eady

Terri McMinn

Lvnne Fenner

Sandra Gray

Lura McKnight

Wendi Welch

Henrietta Hardin

Karen Leib

Katie Gore

Tennessee EIP

John Townes

Jamie Thompson

William Schaffner

Mary Lou Lindegren

Carmen Ford-Treacy

Maryland EIP

•

- Lee Harrison
- David Blythe
- Patricia Ryan
- Rosemary Hollick
- Joanne Benton
- Terresa Carter
- Kim Holmes
- Kathleen Shutt
- Lindsay Saxman
- Andrea Riner
- Mary Messenger
- Helen Yoon
- Carolyn Kreiner

Minnesota EIP

- Richard Danila
- Ruth Lynfield
- Catherine Lexau
- Lori Triden
- Brenda Jewell
- Lindsay Lesher
- Corinne Holtzmann
- Christine Lees
- Craig Morin
- Lisa Dunning
- Valerie Solovjoys
- Billie Juni

New Mexico EIP

- Joan Baumbach
- Megin Nichols
- Joseph Bareta
- Sarah Khalnlian
- Robert Mansmann
- Lisa Butler
- Kathy Angeles
- Gabriela Keener

Thank you!

- New York City DHMH
 - Jennifer Rosen

•

- Sarah Borderud
- Utah Dept. of Health
 - Kristina Russell
 - Melissa Stevens

CDC ABCs Team

- Gayle Fischer Langley
- Chris Van Beneden
- Emily Weston
- Londell McGlone
- Carolyn Wright
- Karrie-Ann Toews
- Ruth Link-Gelles
- Ryan Gierke

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

Tamara Pilishvili

Matt Moore

Amanda Cohn

Elizabeth Briere

Jessica MacNeil

Amanda Faulkner

Tami Skoff

Elizabeth Zell

Melissa Lewis

Tracy Pondo

Scott Fridkin

Fernanda Lessa

Sandie Bulens

Shierley Zhang

Ruth Belflower

Bernie Beall

Dee Jackson

Raydel Mair

Greg Fosheim

Valerie Schoonover 12

Lesley McGee

Logan Sherwood

Leonard Mayer

Jennie Thomas

Tom Taylor

Stephanie Schrag

Nancy Messonnier

Cyndy Whitney